Incidence and course of COVID-19 hospitalizations among patients with familial Mediterranean fever
| Autor: | Ariel Kenig, Fadi Kharouf, Menachem Bitan, Yuval Ishay, Eldad Ben-Chetrit |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Concise Report Coronavirus disease 2019 (COVID-19) Population Familial Mediterranean fever Severity of Illness Index colchicine Young Adult Therapeutic approach Rheumatology Disease severity Internal medicine medicine Humans Pharmacology (medical) In patient Israel education AcademicSubjects/MED00360 Aged education.field_of_study SARS-CoV-2 business.industry Incidence Medical record Incidence (epidemiology) COVID-19 Middle Aged medicine.disease Familial Mediterranean Fever Hospitalization Case-Control Studies Female business |
| Zdroj: | Rheumatology (Oxford, England) |
| ISSN: | 1462-0332 1462-0324 |
| DOI: | 10.1093/rheumatology/keab577 |
| Popis: | Objectives To evaluate the incidence of hospitalization for coronavirus disease 2019 (COVID-19) in patients with FMF, as compared with the general population, and to compare the disease course between FMF inpatients, and age-, sex-, ethnicity- and comorbidity-matched non-FMF COVID-19 inpatients. Methods We used electronic medical records to obtain data about the total number of the insured population and the number of FMF patients in the two largest health management organizations in Jerusalem, Clalit and Meuhedet. The total number of COVID-19 inpatients at the Hadassah Medical Center, including those with FMF, for the period between 1 February 2020 and 10March 2021, was retrieved from the electronic medical records of Hadassah. COVID-19 course was compared between the FMF inpatient group and age-, sex-, ethnicity- and comorbidity-matched non-FMF COVID-19 inpatients. Each FMF inpatient was matched with two non-FMF controls. Results We found no statistically significant difference in the odds of hospitalization for COVID-19 between FMF patients and the non-FMF population (0.46% vs 0.41%, P = 0.73). Furthermore, we found similar disease severity and therapeutic approach in FMF COVID-19 inpatients and matched non-FMF COVID-19 inpatients. Conclusions Neither FMF nor baseline colchicine therapy, appear to affect the incidence of hospitalization for COVID-19 or the disease course, in terms of severity and therapeutic approach. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|